2018 № 8 Causes and models of transformation of strategies for technological development of transnational pharmaceutical companies
During the last ten years, the largest pharmaceutical manufacturers significantly changed their approaches to the formation of their own strategies for capturing and retaining the leading positions in global markets. One of the key prerequisites was a decline in the return on investment in R & D: if in 2010 among the top 12 pharmaceutical companies of the world this indicator was 10.1%, then in 2017 it fell to 3.2%. At the same time, the cost of devel¬oping and launching new medicines has increased: from $1.2 billion to $2 billion in 2010–2017. The article analyzes the main reasons for the transformation of the strategies of the Big Pharma companies. It has been suggested that, in the context of a decline in payback in R & D, increased competition, a fall in public expen¬diture on the purchase of pharmaceuticals, and tightening of regulatory requirements, it is advisable for domestic companies to reorient the creation of corporate venture funds and investing in start-ups, and actively use the mergers and acquisitions strategy
2020 № 4 Evaluation of the prospects for developing a vaccine against coronavirus infection by means of patent analysis
A cross-country comparison of the patent activity of various countries in the field of the development of antiviral drugs, in particular vaccines against coronavirus infection, was carried out. The companies with the most voluminous and authoritative portfolios of patent documents have been identified. Particular attention was paid to the practices used by pharmaceutical companies in the face of intense competition. The importance of protecting the rights to technical solutions with patents issued outside the Russian Federation has been shown.